Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 88.66M | 87.69M | 84.82M | 65.27M | 34.90M | 20.75M |
Gross Profit | 72.55M | 72.43M | 73.40M | 57.70M | 32.38M | 18.55M |
EBITDA | -30.46M | -30.67M | -24.94M | -94.73M | -54.49M | -119.54M |
Net Income | -28.23M | -29.67M | -21.43M | -96.33M | -56.34M | -118.34M |
Balance Sheet | ||||||
Total Assets | 112.61M | 119.90M | 127.87M | 141.46M | 212.78M | 132.05M |
Cash, Cash Equivalents and Short-Term Investments | 60.31M | 67.23M | 78.64M | 105.76M | 181.56M | 114.63M |
Total Debt | 603.00K | 820.00K | 1.42M | 1.77M | 3.63M | 3.98M |
Total Liabilities | 23.16M | 27.90M | 26.88M | 32.23M | 32.68M | 26.21M |
Stockholders Equity | 89.46M | 92.00M | 100.98M | 109.22M | 180.11M | 105.84M |
Cash Flow | ||||||
Free Cash Flow | -19.27M | -15.71M | -27.23M | -75.92M | -103.52M | -91.41M |
Operating Cash Flow | -19.15M | -15.71M | -27.23M | -75.92M | -102.56M | -91.23M |
Investing Cash Flow | -127.00K | 0.00 | 0.00 | 0.00 | 61.04M | -2.79M |
Financing Cash Flow | 3.84M | 4.31M | 100.00K | 84.00K | 108.31M | 2.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $224.09M | ― | -43.28% | ― | -3.92% | -18.67% | |
56 Neutral | $238.83M | ― | -74.15% | ― | -3.61% | -3.39% | |
55 Neutral | $364.29M | ― | -86.53% | ― | -7.84% | 42.34% | |
49 Neutral | AU$2.47B | 4.40 | -64.25% | 2.83% | 36.51% | 13.14% | |
45 Neutral | $161.34M | ― | -20.42% | ― | -18.80% | 26.16% | |
44 Neutral | $192.96M | ― | -29.93% | ― | 3.38% | -36.40% | |
34 Underperform | $281.68M | ― | -34.97% | ― | ― | -140.77% |
Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.